Recent Finacing
Recent Raise
Icosavax develops computationally designed, self-assembling virus-like-particle vaccines, applying its VLP platform—licensed from the University of Washington—to RSV/hMPV bivalent and SARS‑CoV‑2 clinical candidates.
Focus Areas
Recent Investors
Valuation as of 03/19/2021
Total Raised
Funding rounds
Investors
See the team members at Icosavax.
